We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adding methotrexate to adalimumab therapy significantly ...

Background We report on a patient with rheumatoid arthritis (RA) who was treated with adalimumab and retrospectively diagnosed as having a multiple myeloma. Investigations In addition to the ...

May 27, 2010 — The tumor necrosis factor (TNF)–α inhibitor adalimumab may be helpful as adjunct treatment of sciatica, according to the results of a multicenter, randomized, double-blind, ...

Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

Please provide your email address to receive an email when new articles are posted on . In the randomized, double-blind phase 3 study ENVISION I, Croft and colleagues analyzed data from 93 children ...

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...

Adalimumab (Humira) in addition to surgery for moderate to severe hidradenitis suppurativa (HS) significantly increased the rate of complete response versus surgery alone, a first-ever randomized ...

Adalimumab is an effective therapy for patients with noninfectious uveitis, but is associated with more adverse effects than placebo, according to a recent phase 3 clinical trial (VISUAL I). These ...

WASHINGTON, DC—Use of weekly adalimumab in children with juvenile idiopathic arthritis (JIA), pediatric chronic uveitis, and other childhood rheumatic diseases is safe and effective, with 90% having a ...

"Targeted adalimumab treatment can optimize long-term outcomes for patients with early rheumatoid arthritis, study suggests." ScienceDaily. www.sciencedaily.com / releases / 2011 / 05 / ...

NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...

The results of two phase 3 clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurtiva are now being published. An inhibitor ...